USE OF FASL OR FASL TRANSFECTED CD4+/FASL-/TH1-CELL LINES FOR THE TREATMENT OF TH1/TH2 DISEASES

摘要

Disclosed are the use of FasL as active pharmacological component in the treatment of TH1/TH2 diseases, compositions containing FasL and one or more cytokines, specially interferon-.gamma., the use of a composition according to claims 11 and 12 for the treatment of TH1/TH2 diseases, the use of autologous Cd4+/FasL-/TH1 cell lines of the patient, transfected with the FasL gene sequence or with physiologically active fragments of the FasL gene sequence for the treatment of TH1/TH2 diseases.